Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 18/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12026454 | 0.81 | NAMPT (0.43) | HRH3KCNH2CYP2D6 | |
| SCHEMBL13808561 | 0.71 | HTT (0.59) | HRH3KCNH2CYP2D6 | |
| SCHEMBL25581236 | 0.71 | HRH3 (0.36) | HRH3KCNH2 | |
| SCHEMBL25443839 | 0.71 | HRH3 (0.48) | HRH3KCNH2CYP2D6 | |
| SCHEMBL24671761 | 0.71 | NCF1 (0.46) | HRH3KCNH2NCF1 | |
| SCHEMBL18433703 | 0.71 | CHRM1 (0.38) | HRH3KCNH2CYP2D6 | |
| SCHEMBL13300929 | 0.70 | HRH3 (0.46) | HRH3KCNH2NCF1 | |
| SCHEMBL19239928 | 0.69 | KDM5A (0.32) | — | |
| SCHEMBL1261174 | 0.68 | HRH3 (0.44) | HRH3KCNH2CYP2D6 | |
| SCHEMBL25630382 | 0.68 | NCF1 (0.43) | HRH3NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718803-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20160102075-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2016-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102075-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | HRH3 3292/4885KCNH2 3476/4885CYP2D6 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.